Brokerages Set Novartis AG (NVS) PT at $83.32

Novartis AG (NYSE:NVS) has been assigned an average rating of “Hold” from the twenty research firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $85.13.

A number of analysts recently issued reports on NVS shares. TheStreet raised Novartis AG from a “c+” rating to a “b” rating in a research report on Friday, June 2nd. Zacks Investment Research raised Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research report on Tuesday. Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a research report on Thursday, June 22nd. Cowen and Company set a $77.00 price objective on Novartis AG and gave the stock a “hold” rating in a research report on Tuesday, July 11th. Finally, BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th.

Shares of Novartis AG (NYSE NVS) traded down 0.08% during mid-day trading on Friday, hitting $85.78. 2,009,254 shares of the stock were exchanged. The company has a 50-day moving average price of $84.30 and a 200-day moving average price of $80.50. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a market cap of $200.97 billion, a price-to-earnings ratio of 31.32 and a beta of 0.74.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period last year, the company earned $1.23 EPS. Equities analysts expect that Novartis AG will post $4.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/09/20/brokerages-set-novartis-ag-nvs-pt-at-83-32.html.

In other news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.01% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. City Holding Co. boosted its holdings in Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after acquiring an additional 54 shares during the period. WFG Advisors LP boosted its holdings in Novartis AG by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after acquiring an additional 337 shares during the period. TCI Wealth Advisors Inc. boosted its holdings in Novartis AG by 20.0% during the 1st quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after acquiring an additional 230 shares during the period. Archford Capital Strategies LLC boosted its holdings in Novartis AG by 72.3% during the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after acquiring an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC boosted its holdings in Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after acquiring an additional 49 shares during the period. Institutional investors own 10.93% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply